Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) Shares Outstanding (Weighted Average) (2023 - 2025)

CG Oncology's Shares Outstanding (Weighted Average) history spans 3 years, with the latest figure at $77.3 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 23.69% year-over-year to $77.3 million; the TTM value through Dec 2025 reached $77.3 million, up 23.69%, while the annual FY2025 figure was $77.3 million, 23.69% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $77.3 million in Q4 2025 per CGON's latest filing, up from $76.7 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $77.3 million in Q4 2025 to a low of $3.9 million in Q1 2023.
  • Average Shares Outstanding (Weighted Average) over 3 years is $46.3 million, with a median of $59.7 million recorded in 2024.
  • Peak YoY movement for Shares Outstanding (Weighted Average): soared 1556.5% in 2024, then rose 14.28% in 2025.
  • A 3-year view of Shares Outstanding (Weighted Average) shows it stood at $4.3 million in 2023, then soared by 1343.03% to $62.5 million in 2024, then grew by 23.69% to $77.3 million in 2025.
  • Per Business Quant, the three most recent readings for CGON's Shares Outstanding (Weighted Average) are $77.3 million (Q4 2025), $76.7 million (Q3 2025), and $76.2 million (Q2 2025).